Read by QxMD icon Read

Journal of Drug Targeting

Leila Farahmand, Behrad Darvishi, Malihe Salehi, Sarvnaz Samadi Kouchaksaraei, Keivan Majidzadeh-A
Today, intratumoural heterogeneity has been recognised as one of the main causes of cancer treatment failure and drug resistance development through which multiple mechanisms are simultaneously involved. From the broad diversity of cells presented in tumour microenvironment, owing to their proliferative potential and longevity, cancer stem cells (CSCs), are the main cell subpopulation involved in tumour development, propagation, metastatic dissemination and induction of intratumoural heterogeneity. Accordingly, selective targeting and eradication of CSCs may represent a promising approach for cancer therapy and evading drug resistance development...
November 23, 2017: Journal of Drug Targeting
Md Rizwanullah, Saima Amin, Showkat Rasool Mir, Khalid Umar Fakhri, Mohd Moshahid Alam Rizvi
Cancer continues to be one in all the leading reasons for death worldwide. The mean cancer survival through standard therapeutic strategies has not been significantly improved over the past few decades. Hence, alternate remedies are needed to treat this terrible disease. Recently, natural compounds present in the plants, i.e. phytochemicals have been widely exploited for their anticancer potential. Phytochemicals may exhibit their anticancer activity through targeting different cancer cell signaling pathways, promoting cell cycle arrest and apoptosis, regulating antioxidant status and detoxification...
November 21, 2017: Journal of Drug Targeting
Uyen Minh Le, Amanda Hartman, Gopalakrishna Pillai
Pancreatic cancer is one of the most malignant cancers with a high mortality rate. Some types of pancreatic cancer cells overexpress epidermal growth factor receptor (EGFR), which is a potential target for anticancer agents. In this study, we examined the effect of epidermal growth factor (EGF)-conjugated liposomes containing curcumin (EGF-LP-Cur) on three different EGFR-expressed human pancreatic cancer cell lines, BxPC-3, Panc-1, and Mia Paca-2. We have demonstrated that it is feasible to prepare liposomal vesicles of EGF-LP-Cur and that it is stable in the liquid vehicle at ambient conditions for 3 weeks...
November 20, 2017: Journal of Drug Targeting
Khaled Greish, Maryam Fateel, Sara Abdelghany, Nanitha Rachel, Houman Alimoradi, Moiz Bakhiet, Ahmed Alsaie
Sildenafil is an approved drug for the treatment of erectile dysfunction. The drug exerts its action through the relaxation of smooth muscles and the modulation of vascular endothelial permeability. In this work, we tested whether the aforementioned effects of Sildenafil on tumor vasculatures could result in an improvement of anticancer drug concentration in tumor tissues, and hence improve its anticancer effect. Sildenafil when added to doxorubicin showed synergistic anticancer activity against 4T1 breast cancer cells in vitro...
November 17, 2017: Journal of Drug Targeting
Junxia Wang, Wuli Zhao, Hong Liu, Hongwei He, Rongguang Shao
Human myofibrillogenesis regulator 1 (MR-1) is a functional gene also known as paroxysmal nonkinesigenic dyskinesia (PNKD). It is localised on human chromosome 2q35 and three different isomers, MR-1L, MR-1M and MR-1S, are formed by alternative splicing. MR-1S promotes cardiac hypertrophy and is closely related to cancer. MR-1S is overexpressed in haematologic and solid malignancies, such as hepatoma, breast cancer and chronic myelogenous leukaemia. MR-1S causes disordered cell differentiation, initiates malignant transformation and accelerates metastasis...
November 15, 2017: Journal of Drug Targeting
Yukinobu Kodama, Hiroki Hanamura, Takahiro Muro, Hiroo Nakagawa, Tomoaki Kurosaki, Tadahiro Nakamura, Takashi Kitahara, Shigeru Kawakami, Mikiro Nakashima, Hitoshi Sasaki
Fetuin is a biocompatible plasma protein and strongly enhances phagocytosis of bacteria, DNA, and apoptotic cells by peripheral blood cells such as monocytes, macrophages, and dendritic cells. We developed a novel gene delivery system: ternary complexes constructed with pDNA, polyethylenimine (PEI), and fetuin. Without covalent binding, fetuin was able to coat pDNA-PEI complexes, and stable anionic nanoparticles formed at a weight ratio greater than 30. Optimized pDNA-PEI-fetuin complexes significantly decreased the cytotoxicity of pDNA-PEI complexes in the melanoma cell line B16F10...
November 13, 2017: Journal of Drug Targeting
Tao Wang, Radhika Narayanaswamy, Huilan Ren, James W Gillespie, Valery A Petrenko, Vladimir P Torchilin
Pancreatic cancer has been a life-threatening illness associated with high incidence and mortality rates. Paclitaxel that causes mitotic arrest in cancer cells disrupting microtubule function is used for pancreatic cancer treatment[1]. Nausea, anorexia and abdominal pain are some of the typical dose-limiting toxicity associated gastrointestinal side effects of the drug[2]. Here we present the use of polymeric mixed micelles to enable a targeted delivery of Paclitaxel and to provide additional advantages such as enhanced drug solubility, bioavailability and minimal dose-limiting toxicity...
November 13, 2017: Journal of Drug Targeting
Ana Luiza Chaves Maia, Carolina de Aguiar Ferreira, André Luis Branco de Barros, Aline Teixeira Maciel E Silva, Gilson Andrade Ramaldes, Armando da Silva Cunha, Diogo Coelho de Pádua Oliveira, Christian Fernandes, Daniel Crístian Ferreira Soares
Despite advances in the development of new therapeutic agents and diagnostic imaging techniques, the 5-year survival of osteosarcoma, the most common type of bone cancer, remains practically unaltered for the last three decades at around 60%. Nanoparticle-based carriers have emerged as new class of drug delivery systems that could potentially overcome conventional chemotherapy limitations, by promoting a better drug biodistribution profile by allowing a preferential accumulation of the drug in the desired tissue, while minimizing non-targeted tissue toxicity, thus resulting in an improved overall therapeutic effectiveness...
November 3, 2017: Journal of Drug Targeting
Kıvılcım Öztürk-Atar, Hakan Eroğlu, Sema Çalış
Developing a new drug molecule is not only time consuming and expensive, but also mostly a failing process. However, improving bioavailability, targetability, efficacy, or safety of old drugs could be more effective way to use them in clinic. For these purposes so many strategies including individualizing drug therapy, nanoparticle based drug delivery systems, drug conjugates, therapeutic drug monitoring, stimuli sensitive targeted therapy are investigated intensely. Depending on the desired application or targeted site, nanoparticles can be administrated as orally, locally, topically, and systemically...
November 3, 2017: Journal of Drug Targeting
Sebastien Taurin, Aliyah A Almomen, Tatianna Pollak, Sun Jin Kim, John Maxwell, C Matthew Peterson, Shawn C Owen, Margit M Janát-Amsbury
Vaginal drug delivery represents an attractive strategy for local and systemic delivery of drugs otherwise poorly absorbed after oral administration. The rather dense vascular network, mucus permeability and the physiological phenomenon of the uterine first-pass effect can all be exploited for therapeutic benefit. However, several physiological factors such as an acidic pH, constant secretion, and turnover of mucus as well as varying thickness of the vaginal epithelium can impact sustained drug delivery. In recent years, polymers have been designed to tackle challenges mentioned above...
November 3, 2017: Journal of Drug Targeting
Chun Y Wong, Hani Al-Salami, Crispin R Dass
Therapeutic peptides are conventionally administered via subcutaneous injection. Chitosan-based nanoparticles are gaining increased attention for their ability to serve as a carrier for oral delivery of peptides and vaccination. They offered superior biocompatibiltiy, controlled drug release profile, and facilitated gastrointestinal absorption. The encapsulated peptides can withstand enzymatic degradation and various pH. Chitosan-based nanoparticles can also be modified by ligand conjugation to the surface of nanoparticle for transcellular absorption and specific-targeted delivery of macromolecules to the tissue of interest...
November 2, 2017: Journal of Drug Targeting
Ankush Sharma, Amit K Goyal, Goutam Rath
Metal nanoparticles may have the potential to overcome problems related to conventional chemotherapy. Metal nanoparticles reported to play a beneficial and powerful role in cancer therapy providing better targeting, gene silencing and drug delivery. Functionalized metal nanoparticles with targeting ligands offer a better control of energy deposition in the tumors. Apart from therapeutic benefits, metal nanoparticles are also used as a diagnostic tool for the imaging of cancer cells. Metal nanoparticle-based therapeutic systems not only provide simultaneous diagnostic and therapy but also allow controlled and targeted drug release helps to revolutionize cancer treatment and management...
November 2, 2017: Journal of Drug Targeting
Noha Nafee, Mariam Zewail, Nabila Boraie
Alendronate (ALN) is a BCS III bone resorption inhibitor, with very poor oral bioavailability. Our approach is to develop a minimally invasive thermogelling system for prolonged local delivery of ALN. For this, different chitosan-based thermogels were developed and characterised in terms of gelation time, injectability, pH, viscosity and thermoreversibility. Chitosan/β-glycerophosphate (CS/βGP) hydrogel pursued temperature-dependent, thermoreversible gelation behaviour and was thus selected for drug loading...
October 26, 2017: Journal of Drug Targeting
Uday Krishna Baruah, Kuppusamy Gowthamarajan, Vanka Ravisankar, Veera Venkata Satyanarayana Reddy Karri, Praveen Kumar Simhadri, Vineeta Singh
Chloroquine was once the most widely used antimalarial for nearly eight decades for its safety, efficiency, stability, low cost and finally for its less toxic nature. But its use and efficacy got slowly decreased with the increase of chloroquine resistant strains of Plasmodium species throughout the world. Lipid based nanodrug delivery systems have been very popular in the recent times as they are very less toxic, have drug targeting capabilities and also reduces the dosing frequency by increasing efficacy of the drug...
October 23, 2017: Journal of Drug Targeting
Délia Chaves Moreira Dos Santos, Marselle Leite Silvério de Souza, Eliane Morais Teixeira, Líndicy Leidicy Alves, José Mário Carneiro Vilela, Margareth Andrade, Maria das Graças Carvalho, Ana Paula Fernandes, Lucas Antônio Miranda Ferreira, Marta Marques Gontijo Aguiar
This work aimed to optimise a new nanoemulsion (NE) formulation loaded with Amphotericin B (AmB) and to evaluate its in vivo antileishmanial activity and in vitro haemolytic toxicity. The influence of gradual increases in pressure, using a high-pressure homogeniser, was evaluated. The NE was characterised for droplet size, polydispersity index, zeta potential and encapsulation efficiency (EE). For antileishmanial activity studies, AmB-NE was administered intravenously in mice infected by Leishmania infantum chagasi, which causes Visceral Leishmaniasis (VL)...
October 18, 2017: Journal of Drug Targeting
Yosuke Takahashi, Yuki Araie, Daiki Nomura, Yuki Takahashi, Kohei Sano, Hideo Saji, Yoshinobu Takakura, Makiya Nishikawa
Phosphorodiamidate morpholino oligonucleotides (PMOs) are a class of antisense oligonucleotides used in the treatment of neuromuscular diseases. Their major drawbacks are high blood clearance and poor cellular delivery. Previously, we demonstrated that tripod-like nanostructured DNA, or tripodna, was efficiently taken up by macrophages and dendritic cells. In this study, we used iodine-125((125)I)-labelled PMOs, designed a tripodna harbouring an (125)I-PMO ((125)I-PMO/tripodna), and evaluated whether this tripodna could control the pharmacokinetic properties of PMO...
October 3, 2017: Journal of Drug Targeting
Kamyar Khoshnevisan, Maryam Daneshpour, Mohammad Barkhi, Morteza Gholami, Hadi Samadian, Hassan Maleki
Fabrication and characterization of gold nanoparticles (GNPs) through reducing agents and different capped agents are one of their most attractive applications in biomedicine. GNPs are coated using various agents such as carbohydrate, amino acids, peptides, and proteins. These capped gold nanoparticles (C-GNPs) are applied for wide different applications including drug delivery in the recent decade and potential treatment and diagnosis in drug delivery systems (DDS). Recent studies have shown that these novel compounds and conjugated-nanoparticles drugs play a key role for the promising cure of high-risk refractory diseases...
October 3, 2017: Journal of Drug Targeting
Atefeh Arab, Javad Behravan, Atefeh Razazan, Zahra Gholizadeh, Amin Reza Nikpoor, Nastaran Barati, Fatemeh Mosaffa, Ali Badiee, Mahmoud Reza Jaafari
E75 (HER-2/neu-369-377), is an immunogenic peptide which is highly expressed in breast cancer patients. The purpose of this study was to develop an effective vaccine delivery/adjuvant system by attachment of this peptide to the surface of liposomes consisting of phospholipids including DSPC and DSPG with high transition temperature (Tm) and DOPE (a pH-sensitive lipid for cytosolic antigen delivery) to improve anti-tumor immune activity against the E75 peptide. For this purpose, the E75 peptide was incorporated into liposomes consisting of DSPC/DSPG/Chol/DOPE (15/2/3/5 molar ratio) through conjugation with maleimide-PEG2000-DSPE...
October 3, 2017: Journal of Drug Targeting
Hiroshi Maeda
History of the EPR (enhanced permeability and retention) effect is discussed, which goes back to the analyses of molecular pathology in bacterial infection and edema (extravasation) formation. The first mediator we found for extravasation was bradykinin. Later on, were found nitric oxide and superoxide, then formation of peroxynitrite, that activates procollagenase. In this inflammatory setting many other vascular mediators are involved that are also common to cancer vasculature. Obviously cancer vasculature is defective architechtally, and this makes macromolecular drugs more permeable through the vascular wall...
November 2017: Journal of Drug Targeting
Saghir Akhtar
No abstract text is available yet for this article.
November 2017: Journal of Drug Targeting
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"